Peptides DB
Research-centric peptide and protocol reference hub
Study 13 of 24Goserelin literaturebiorxiv-preprint · Observational2026

Impact of Lifestyle Patterns on Breast Cancer Prognosis: Evidence from a UK Biobank Survival Study

Lifestyle habits significantly influence breast cancer survival, with age and BMI being critical factors. This study provides a foundation for integrating health indicators into risk assessment models.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the goserelin corpus
4
Preclinical
14
Observational · this one
0
Open-label
5
Randomised
1
Reviews

Summary and findings

This study analyzed the impact of lifestyle habits on breast cancer survival in 14,901 female patients from the UK Biobank. Key factors identified included age, BMI, alcohol intake, and smoking status. The eXtreme Gradient Boosting model showed predictive performance with AUC values of 0.72 at 3 years, 0.727 at 6 years, and 0.749 at 9 years.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
3-year AUC = 0.72 for breast cancer survival prediction.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>Background:</bold> Understanding how lifestyle habits influence breast cancer survival is crucial for improving long-term outcomes and guiding individualized care. The purpose of this study is to comprehensively understand how dietary habits, exercise frequency, sleep quality and the frequency of tobacco and alcohol use affect the survival of breast cancer patients by analyzing the synergistic effects of multiple lifestyle habits. <bold>Methods:</bold> We analyzed data from 14,901 female breast cancer patients in the UK Biobank, a large-scale population-based cohort. Three feature selection methods were applied to identify key prognostic variables. Five survival risk models were compared to investigate the relationship between breast cancer survival and lifestyle habits. Kaplan-Meier survival analysis and SHapley Additive exPlanations (SHAP) interpretability analysis were performed on risk scores calculated from the best-performing model. <bold>Results:</bold> Through feature selection, we identified that age, number of medications taken, Body Mass Index (BMI), alcohol intake, diastolic blood pressure and smoking status were pinpointed as critical characteristics influencing the survival of breast cancer patients. Among all models, the eXtreme Gradient Boosting (XGBoost) model demonstrated the highest predictive performance (3 years: AUC = 0.72, 6 years: AUC = 0.727, 9 years: AUC = 0.749). Kaplan-Meier analysis showed that patients classified as high-risk based on the median risk score had significantly worse survival outcomes ( <italic>P</italic>  < 0.0001). SHAP analysis further confirmed the dominant influence of age and BMI on mortality risk. <bold>Conclusions:</bold> This study highlights the prognostic value of lifestyle habits in breast cancer survival. By integrating routine health indicators into interpretable machine learning models, our findings provide a practical foundation for individualized risk assessment and lifestyle-based intervention strategies. </p>

Elsewhere in the Goserelin corpus

AAssessing the Feasibility of a Self-Management Intervention for Individuals With Advanced Prostate Cancer and Comorbid Type II Diabetes Mellitus.Cancer medicine · 2026 · n=28 · > 75% engagement and average acceptability score of 37.3/56.HumanBFrom Treatment Discontinuation to Aggressive Recurrence: A Cautionary Case Report of Rapid Progression to Invasive Carcinoma Following Torimifene-Induced Hepatotoxicity and Drug Withdrawal in a Patient With Completely Resected Intraductal Papillary Carcinoma.Clinical case reports · 2026 · n=1HumanAImpact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.The Canadian journal of urology · 2026 · n=174 · Not reported in abstract.HumanBDrug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.Expert opinion on drug safety · 2025 · n=33948 · Median weight for GLP-1 analogues was 91 kg, and for compound hypoglycemic agents was 82 kg, p < 0.01.reviewBClinical pathological changes in prostate cancer patients after hormonal therapy: A single-center pilot study.Biochemistry and biophysics reports · 2026 · n=32 · Corrected mean AUC was 0.725 (95% CI: 0.58-0.87).HumanAFovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.JAMA oncology · 2026 · n=417 · Median PFS not reached vs 20.2 months with placebo, HR 0.55, 95% CI 0.38-0.77, 1-sided P < .001.Human